JW Therapeutics' leadership says the firm’s operations and international partnerships have not been affected by Beijing’s stepped-up review of transactions involving sensitive technologies. Chief Executive Leo Tian emphasized that the company’s cross-border work, particularly in cell and gene therapies (CGT), remains dependent on international cooperation and that he has not observed any impact to date.
Industry interest in China-developed experimental medicines has been growing as multinational drugmakers search for new assets while managing costs ahead of looming patent expirations. Analysts cited in market commentary expect a surge in biotech licensing deals this year, potentially setting a new record.
At the same time, regulators in China have recently taken a firmer stance on certain foreign acquisitions. The government ordered a U.S. technology company to reverse an acquisition of an artificial intelligence startup valued at more than $2 billion, part of broader measures to increase oversight of U.S. investment in domestic firms working on frontier technologies. That action has been described as sending a chill across multiple industries and raising the perceived risk for global investors with exposure to advanced-technology firms that maintain ties to China.
For JW, whose largest shareholder is U.S. drugmaker Bristol Myers Squibb via that firm’s wholly owned subsidiary Juno Therapeutics, the focus remains on advancing its cell immunotherapy products. Tian said the company is actively pursuing collaborations with overseas partners for assets in its pipeline.
The company’s public comments indicate confidence in the resilience of its cross-border collaborations even as scrutiny of certain types of deals has intensified. JW’s emphasis on CGT underlines the sector’s dependence on international scientific exchange and external partnerships for development and commercialization.
Market observers continue to monitor whether heightened regulatory reviews of foreign investments and acquisitions will translate into broader constraints on transactions involving advanced technologies or produce knock-on effects across adjacent sectors. For now, JW’s management reports business-as-usual in its development programs and external partnership efforts.